Welcome to our dedicated page for Y-Mabs Therapeutics SEC filings (Ticker: YMAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Y-mAbs Therapeutics, Inc. (YMAB) SEC filings archive on this page provides a record of the company’s historical regulatory disclosures as a former Nasdaq-listed issuer and documents its transition to a privately held subsidiary of an affiliate of SERB Pharmaceuticals. While Y-mAbs has since terminated registration of its common stock and suspended its reporting obligations, these filings remain an important source of information for understanding its past operations, capital structure, and corporate transactions.
Among the most significant filings for Y-mAbs are its current reports on Form 8-K. A Form 8-K dated August 5, 2025 describes the Agreement and Plan of Merger between Y-mAbs, Perseus BidCo US, Inc. (Parent), and Yosemite Merger Sub, Inc. (Purchaser), under which Parent agreed to cause Purchaser to commence a cash tender offer for all outstanding shares of Y-mAbs common stock at $8.60 per share. A subsequent Form 8-K dated September 16, 2025 reports the completion of the tender offer and the merger under Section 251(h) of the Delaware General Corporation Law, the resulting change of control, and the conversion of each outstanding share (other than specified excluded shares) into the right to receive the cash merger consideration.
These 8-K filings also explain the delisting and deregistration process. In connection with the merger, Y-mAbs requested that the Nasdaq Global Select Market suspend trading in its common stock and file a Form 25 to remove the shares from listing and registration under Section 12(b) of the Securities Exchange Act of 1934. The Form 25-NSE filed on September 16, 2025 by Nasdaq Stock Market LLC serves as the official notification of removal from listing and/or registration. A later Form 15, filed on September 26, 2025, certifies the termination of registration under Section 12(g) and the suspension of Y-mAbs’ duty to file periodic reports under Sections 13 and 15(d). The Form 15 notes that the approximate number of holders of record at the certification date was one.
Earlier and contemporaneous filings, including Forms 10-K and 10-Q referenced in company press releases, contain detailed financial statements, risk factors, and management discussion and analysis related to Y-mAbs’ commercial-stage biopharmaceutical business. These documents discuss revenue from DANYELZA® (naxitamab-gqgk), research and development expenses for SADA PRIT programs such as GD2-SADA and CD38-SADA, selling, general, and administrative costs, and other operating metrics. While these periodic reports are no longer being updated following deregistration, they provide historical context on the company’s financial profile and R&D investment patterns during its time as a public company.
For those examining equity and compensation structures, the merger-related 8-K details the treatment of stock options, restricted stock units (RSUs), and performance-based RSUs (PSUs) at the effective time of the merger, including cash-out provisions and cancellation of options with exercise prices at or above the merger consideration. Additional filings, such as proxy statements and Section 16 reports (Forms 3, 4, and 5), historically provided insight into director and executive equity holdings and changes in beneficial ownership.
On this page, Stock Titan surfaces Y-mAbs’ historical SEC filings with real-time retrieval from EDGAR and AI-powered summaries that explain the core points of each document in accessible language. Users can quickly identify key merger terms, delisting steps, and financial reporting highlights without reading every page of the underlying forms. For deeper analysis, the full-text filings remain available for review, allowing investors, researchers, and legal or compliance professionals to trace the complete regulatory history of Y-mAbs Therapeutics, Inc. under the former ticker YMAB.
Y-mAbs director Laura Hamill reported that pursuant to a merger transaction on 09/16/2025 she disposed of all her company equity for cash consideration of $8.60 per share. The Form 4 shows 5,825 common shares tendered and 25,080 RSUs converted into cash, leaving 0 shares beneficially owned. Outstanding stock options were also cancelled or cashed out: several options were converted into cash based on the difference between the $8.60 merger price and their exercise prices, while any option with an exercise price equal to or above $8.60 was cancelled for no consideration. The reporting person’s position in Y-mAbs is fully eliminated as a result of the merger.
WG Biotech ApS reported the disposition of all its Y-mAbs Therapeutics (YMAB) common shares in connection with a completed merger. On 09/16/2025 Purchaser completed a tender offer and merged into the issuer, and each outstanding share was cancelled for $8.60 per share in cash. WG Biotech ApS surrendered 4,559,233 shares and reports beneficial ownership of 0 shares following the transaction. The filing notes Johan Wedell-Wedellsborg is the majority owner of WG Biotech ApS and had sole voting and dispositive power over the shares; he served as a director. The footnotes state the descriptions are qualified by the Merger Agreement.
Y-mAbs Therapeutics insiders had outstanding stock options converted into cash as part of a completed merger. Under the merger agreement, each option outstanding immediately prior to the merger was canceled and converted into the right to receive cash equal to the number of shares subject to the option multiplied by the excess of the $8.60 per share merger consideration over the option exercise price. Options with an exercise price equal to or above the merger consideration were canceled without any payment. The reporting form shows an employee stock option with a $6.16 exercise price covering 142,600 shares that was converted into the right to receive cash for the difference between $8.60 and $6.16 per share.
Y-mAbs Therapeutics completed a merger and associated tender offer resulting in cash-out of outstanding equity awards. On 09/16/2025 the purchaser completed a tender offer and merged with the issuer, making Y-mAbs an indirect wholly owned subsidiary of the buyer. Common shares were cancelled and converted into $8.60 per share in cash. The reporting person, a director, disposed of 5,825 shares and 25,080 restricted stock units were cashed out. All outstanding stock options and RSUs were cancelled and converted into cash pursuant to the merger terms, with options yielding cash equal to the excess of $8.60 over each option's exercise price; options with exercise prices at or above $8.60 were cancelled for no consideration.
Y-mAbs Therapeutics insider report shows completion of a merger and cash-out of equity awards. On 09/16/2025 the reporting person, Director Ashu Tyagi, had 5,825 shares tendered for $8.60 per share and 25,080 restricted stock units cancelled for cash under the Merger Agreement. Outstanding stock options were cancelled and converted into cash based on the excess of the $8.60 merger consideration over each option's exercise price; options with exercise prices at or above $8.60 were cancelled for no consideration. Following the transactions the reporting person reports 0 shares beneficially owned.
Y-mAbs Therapeutics completed a merger on September 16, 2025 that resulted in all outstanding common shares and equity awards being cashed out. Under the Merger Agreement, each share was exchanged for $8.60 in cash and the company became an indirect wholly owned subsidiary of Perseus BidCo US, Inc. and its ultimate parent. The reporting person, Thomas Gad, disposed of or had converted into cash his directly and indirectly held common stock, restricted stock units, performance RSUs and stock options; following the transactions the report shows zero shares beneficially owned. Options with exercise prices equal to or above $8.60 were cancelled for no consideration, while other vested and unvested awards were converted into cash per the agreement.
Peter P. Freundschuh, EVP, CFO and Treasurer of Y-mAbs Therapeutics, Inc. (YMAB), reported that on 09/16/2025 a merger transaction closed under which his equity awards were cancelled and converted to cash. Pursuant to the Merger Agreement, outstanding restricted stock units (RSUs) and performance RSUs (PRSU) were converted into a cash payout equal to $8.60 per share. Outstanding stock options were cancelled and converted into cash equal to the excess of the $8.60 merger consideration over each option's exercise price; options with exercise prices at or above $8.60 were cancelled without consideration. The Form 4 shows disposition entries on 09/16/2025: 77,800 shares of Common Stock disposed, cancellation/conversion of 170,000 options at $12.47, 63,500 options at $6.16, and two RSU/PRSU line items of 15,900 each. Following the reported transactions the filing reports 0 shares or derivative securities beneficially owned.
Michael J. Rossi, President & CEO and Director of Y-mAbs Therapeutics (YMAB), reported disposition of his equity holdings in connection with a completed merger. Pursuant to a Merger Agreement dated August 4, 2025, a tender offer closed and the company merged into an indirect wholly owned subsidiary of the buyer on September 16, 2025. Each outstanding common share was cancelled for $8.60 per share in cash. The Form 4 shows reported disposals that reduced the reporting person’s direct common stock and derivative positions to zero following the Effective Time, including 7,982 shares and 129,101 RSU-related shares reflected as tendered or cancelled, multiple employee stock options (totaling 1,040,140 options across three series) converted into cash, and several RSU/PRSU awards likewise converted into cash under the Merger Agreement.
The footnotes explain that outstanding options were cashed out for the excess of the $8.60 merger consideration over their exercise prices (options with exercise prices at or above $8.60 were cancelled for no consideration), and that RSUs/PRSUs were converted into the right to receive cash equal to their underlying share count multiplied by $8.60.
Y-mAbs Therapeutics insider reported transactions tied to a completed merger. On September 16, 2025, pursuant to a Merger Agreement, a tender offer and subsequent merger resulted in Y-mAbs becoming an indirect wholly owned subsidiary of Perseus BidCo US, Inc. Common shares were cancelled and converted into cash consideration of $8.60 per share. Reporting person Joris Wilms surrendered 12,799 shares and 39,301 restricted stock units in exchange for the merger consideration, leaving 0 shares beneficially owned post-transaction.
Outstanding employee stock options were cancelled and converted into cash equal to the difference between the $8.60 Merger Consideration and each option's exercise price for in-the-money options; options with exercise prices at or above $8.60 were cancelled for no consideration. The Form 4 discloses the cash-out treatment for RSUs and options under the Merger Agreement.
FAQ
What is the current stock price of Y-Mabs Therapeutics (YMAB)?
What is the market cap of Y-Mabs Therapeutics (YMAB)?
